ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,872.16
-2.95%
US Tech 100
20,828.00
0.82%
Dow Jones
42,326.87
0.00%
Brent Oil
73.005
0.37%
Bitcoin
102,057.32
1.99%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Mesoblast Limited (MESO)

  7. Mesoblast Limited (MESO) News

MESO

Mesoblast (MESO)

Mesoblast Limited
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MESO
DateTimeSourceHeadlineSymbolCompany
12/18/20247:08PMGlobeNewswire Inc.Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) TherapyNASDAQ:MESOMesoblast Limited
12/18/20247:30AMGlobeNewswire Inc.Mesoblast to be Added to Nasdaq Biotechnology IndexNASDAQ:MESOMesoblast Limited
12/13/20244:04PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:MESOMesoblast Limited
12/09/20244:21PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
12/04/20246:32PMGlobeNewswire Inc.FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
12/02/20246:20PMGlobeNewswire Inc.Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With InflammationNASDAQ:MESOMesoblast Limited
11/18/20246:47AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
10/30/20247:11PMGlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024NASDAQ:MESOMesoblast Limited
10/09/20243:42PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MESOMesoblast Limited
09/29/20248:55PMGlobeNewswire Inc.Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product LaunchNASDAQ:MESOMesoblast Limited
08/29/20247:14AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
08/28/20247:27PMGlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024NASDAQ:MESOMesoblast Limited
08/27/20247:25PMGlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
07/30/20249:13PMGlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024NASDAQ:MESOMesoblast Limited
07/23/20247:53AMGlobeNewswire Inc.FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
07/21/20248:45PMGlobeNewswire Inc.Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back PainNASDAQ:MESOMesoblast Limited
07/08/20248:37PMGlobeNewswire Inc.Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
07/01/20241:55AMGlobeNewswire Inc.Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next WeekNASDAQ:MESOMesoblast Limited
06/02/20248:23PMGlobeNewswire Inc.Mesoblast Corporate Presentation at Investor ConferenceNASDAQ:MESOMesoblast Limited
04/29/20249:05PMGlobeNewswire Inc.Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024NASDAQ:MESOMesoblast Limited
03/26/20249:25AMAllPennyStocks.comFDA Commentary Sends Biotech Soaring During Premarket HoursNASDAQ:MESOMesoblast Limited
03/25/202410:34PMGlobeNewswire Inc.United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
03/13/20247:30PMGlobeNewswire Inc.Mesoblast Successfully Completes Placement and Accelerated Entitlement OfferNASDAQ:MESOMesoblast Limited
03/10/20247:54PMGlobeNewswire Inc.United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)NASDAQ:MESOMesoblast Limited
02/28/20245:57PMGlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023NASDAQ:MESOMesoblast Limited
02/26/20247:00AMGlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
02/14/20247:46PMGlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
01/31/20249:34PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
01/30/20249:13PMGlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023NASDAQ:MESOMesoblast Limited
01/18/20247:28PMDow Jones NewsMesoblast Gets FDA's Special Pediatric Designation for Revascor Heart TreatmentNASDAQ:MESOMesoblast Limited
 Showing the most relevant articles for your search:NASDAQ:MESO

Your Recent History

EU
BE0002701820
Bnp Paribas Arbitrage Is...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads